We will be present at « High-Content and Phenotypic Screening » conference in Cambridge (25 – 26 April 2017) to talk about advantages of 3D culture in phenotypic screening, during the user meeting of Molecular Devices.

Cellular assays in 3D culture have shown many advantages to better mimic the in vivo situation. A few examples in oncology, CNS and metabolic diseases, will be presented during this talk. High-Content Screening (HCS) devices, such as the ImageXpress Micro confocal from Molecular Devices, are now fast enough and sensitive enough to allow image acquisition in 3D cellular models. Nevertheless, to go further, perceptions and processes need to be changed. We will discuss cutting-edge new technologies, including virtual and augmented realities, deep learning and machine learning, and explain how these new technologies can be of benefit to phenotypic screening.

If you want to talk with our CEO or our CIO, feel free to send a message with our contact form !


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

A great Molecular Devices user meeting in Cambridge ! | HCS-pharma · May 2, 2017 at 9:03 am

[…] in Cambridge. We were invited by our partner Molecular Devices to give a talk during the “User meeting Molecular Devices” about our vision of 3D culture in phenotypic screening and the impact of new technologies. […]

Leave a Reply